Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Treasury’s Final Earnings Stripping Guidance Keeps Pressure On Inversions

Executive Summary

The US Treasury released final guidance to eliminate one of the economic motivations behind inversion deals, the threat of which in April derailed the Pfizer/Allergan mega merger. It doesn’t, however, affect other practices as feared.

You may also be interested in...



Biden Infrastructure Plan Offers Biopharma R&D Carrot, Tax Stick

Tens of billions would go to fund R&D, including Phase I and Phase II development of vaccines. But the plan would also crack down on inversions and offshoring.

Death And Tax Inversion: Policy Fight Won't Go Away, Now Spawning Lawsuits

US Chamber of Commerce wants court to eliminate IRS rule that blocked Pfizer's acquisition of Allergan; AbbVie hit with second suit over its 2014 proposed acquisition of Shire.

The Fall Of Pfizergan: The Beginning, The End And Everything In Between

The $160bn mega-merger that never came to be was exciting to watch unfold from beginning to the stunning end, when it was derailed by the US government. “The Pink Sheet” followed every twist and turn along the way.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel